2021
DOI: 10.1097/mpa.0000000000001793
|View full text |Cite
|
Sign up to set email alerts
|

Auxora for the Treatment of Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome

Abstract: Supplemental digital content is available in the text.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
43
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 44 publications
(43 citation statements)
references
References 30 publications
0
43
0
Order By: Relevance
“…The compound CM2489 had some chemical improvements and design to treat acute pancreatitis. The preclinical trials were successful in mice, and the phase I clinical trials were successful, allowing entry into phase II with a good safety profile and improvement in patient outcomes [ 245 , 246 ]. In addition, a clinical study, although limited by its design, has been conducted for the treatment of severe or critical COVID-19 pneumonia with this compound [ 247 ].…”
Section: Targeted Soce In Pah: a Novel Therapeutic Option?mentioning
confidence: 99%
“…The compound CM2489 had some chemical improvements and design to treat acute pancreatitis. The preclinical trials were successful in mice, and the phase I clinical trials were successful, allowing entry into phase II with a good safety profile and improvement in patient outcomes [ 245 , 246 ]. In addition, a clinical study, although limited by its design, has been conducted for the treatment of severe or critical COVID-19 pneumonia with this compound [ 247 ].…”
Section: Targeted Soce In Pah: a Novel Therapeutic Option?mentioning
confidence: 99%
“…Based on these preclinical observations, CalciMedica successfully completed two phase I clinical trials and then tested seven patients with AP to assess the pharmacokinetic and pharmacodynamics profile of Auxora when administered by intravenous infusion. Based on these, a phase 2 open-label, dose-response clinical study evaluated the safety of Auxora in patients with AP, systemic inflammatory response syndrome (SIRS) and hypoxaemia (Bruen et al 2021). While low-dose Auxora treatment improved moderate to mild AP in 36.5% of the patients, very interestingly Auxora also improved the tolerance of solid foods, which might be explained by improved exocrine pancreatic secretion.…”
Section: Introductionmentioning
confidence: 99%
“…Based on these, a phase 2 open‐label, dose–response clinical study evaluated the safety of Auxora in patients with AP, systemic inflammatory response syndrome (SIRS) and hypoxaemia (Bruen et al . 2021). While low‐dose Auxora treatment improved moderate to mild AP in 36.5% of the patients, very interestingly Auxora also improved the tolerance of solid foods, which might be explained by improved exocrine pancreatic secretion.…”
Section: Introductionmentioning
confidence: 99%
“…The S1 and RBD-elicited Ca 2+ signals in macrophages and stellate cells, demonstrated in this study, would be likely to exacerbate an otherwise mild case of AP initiated, for example, by the primary action of bile acids or a combination of ethanol and fatty acids on the acinar cells, and could help to explain the known cases of severe AP associated with SARS-CoV-2 infection 4 , 24 . Our finding that the S1- and RBD-elicited Ca 2+ signals can be inhibited by an Orai1 CRAC channel blocker, is a further argument in favour of this pharmacological treatment against AP 5 , 25 .…”
Section: Discussionmentioning
confidence: 63%